Lege Artis Medicinae

[Tempora mutantur]

NEMESÁNSZKY Elemér

JANUARY 20, 2007

Lege Artis Medicinae - 2007;17(01)

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[OUR EXPERIENCE WITH BORTEZOMIB-BASED THERAPY OF MULTIPLE MYELOMA BASED ON THE FIRST 60 PATIENTS]

MIKALA Gábor, BÁTAI Árpád, CEGLÉDI Andrea, CSUKLY Zoltán, DOLGOS János, HALM Gabriella, JÁNOSI Judit, KAPÁS Balázs, LOVAS Nóra, LUEFF Sándor, PETŐ Mónika, REMÉNYI Péter, SIPOS Andrea, TÓTH Zsuzsanna

[INTRODUCTION - Bortezomib, a first-in-itsclass proteasome-inhibitor drug was registered in 2004 for the salvage treatment of relapsed and/or refractory multiple myeloma. We have been using this drug in our department for the treatment of myeloma patients since 2005. PATIENTS AND METHODS - In this retrospective study, treatment results (response rate, response duration, survival) as well as the complications and side effects were analysed based on 60 myeloma patients treated over a period of 18 months. The patients received at least one full cycle of non-first-line bortezomib-based (predominantly combinational) therapy. RESULTS - At least minimal laboratory and/or clinical response was observed in 47 of the 56 patients who could be analysed. Clinically meaningful (at least partial remission) response was seen in 41 of 56 patients. Immune-fixation negative complete remission was achieved in six patients. Median progression-free survival of our patient population was 13 months (10.8-14.8 months, n=49, adjusted for patients lost in the first 6 weeks and for those with less than 6 weeks of follow-up). As for overall survival, the median has not been reached, while treated patients had an 80.3% probability of survival at one year. CONCLUSIONS - Based on the treatment results of 60 myeloma patients, bortezomibbased therapy is clearly effective in relapsed and/or refractory myeloma.]

Lege Artis Medicinae

[The 19th General Assembly of the Hungarian Society on Geriatrics and Gerontology Zalakaros, 9-11 November 2006]

RUSZWURM Andrea

Lege Artis Medicinae

[On the Market]

dr. RIESZ Tamás

Lege Artis Medicinae

[Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding]

NEMESÁNSZKY Elemér

Lege Artis Medicinae

[The Watercolours of Aladár Almásy]

All articles in the issue

Related contents